Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168902 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 2 study of Glaucoma, sponsored by Bausch & Lomb Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
- 8
- Study locations
NCT07168902: Recruiting Phase 2 study of Glaucoma, sponsored by Bausch & Lomb Incorporated.
NCT07168902 is a Phase 2 study of Glaucoma that is actively recruiting participants, run by Bausch & Lomb Incorporated. The registered enrollment target is 228 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168902, a Phase 2 study of Glaucoma, is actively recruiting participants, sponsored by Bausch & Lomb Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
- 8
- Study locations
Study Summary
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
Conditions Studied
Interventions
- DRUG BL1107 Low dose
- DRUG BL1107 High dose
- DRUG Timolol maleate 0.5%
Study Locations (8)
Florida
- Levenson Eye Associates - Jacksonville
- Central Florida Eye Associates - Lakeland
- Lee Shettle Eye and Hearing - Largo
California
- Global Research Management, Inc. - Glendale
- Eye Research Foundation - Newport Beach
Massachusetts
- Andover Eye Associates - Andover
Pennsylvania
- Scott & Christie and Associates, PC - Cranberry Township
Tennessee
- Total Eye Care, P.A. - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT07168902 shows while recruiting
NCT07168902 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which BL1107 Low dose is the first listed.
NCT07168902 lists 8 locations in 5 states (Florida, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT07168902 about?
NCT07168902 is a clinical study titled "Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension". Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
What is the current status of trial NCT07168902?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2025-10-24. Estimated completion is 2026-05.
What conditions does trial NCT07168902 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT07168902?
The interventions under investigation include: BL1107 Low dose (DRUG), BL1107 High dose (DRUG), Timolol maleate 0.5% (DRUG).
Who is sponsoring clinical trial NCT07168902?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07168902 being conducted?
This trial has 8 study locations across California, Florida, Massachusetts, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07168902's enrollment target sits among peer trials
228 24th of 92 higher than 69 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI